Connection

Robert Harrington to Acute Disease

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Acute Disease.
Robert Harrington
Connection Strength
1.413
Acute Disease
  1. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 01; 94(1):21-28.
    View in: PubMed
    Score: 0.137
  2. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018 04; 198:84-90.
    View in: PubMed
    Score: 0.130
  3. Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 12 15; 375(24):e50.
    View in: PubMed
    Score: 0.121
  4. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13; 134(24):1918-1930.
    View in: PubMed
    Score: 0.120
  5. Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. J Cardiovasc Pharmacol Ther. 2016 05; 21(3):227-32.
    View in: PubMed
    Score: 0.111
  6. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. J Interv Cardiol. 2007 Oct; 20(5):299-306.
    View in: PubMed
    Score: 0.064
  7. Women, acute ischemic heart disease, and antithrombotic therapy: challenges and opportunities. Circulation. 2007 Jun 05; 115(22):2796-8.
    View in: PubMed
    Score: 0.062
  8. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005 Nov 01; 96(9):1200-6.
    View in: PubMed
    Score: 0.055
  9. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation. 2004 Feb 10; 109(5):641-6.
    View in: PubMed
    Score: 0.050
  10. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17; 106(12):1470-6.
    View in: PubMed
    Score: 0.045
  11. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation. 2002 Jul 16; 106(3):309-12.
    View in: PubMed
    Score: 0.045
  12. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002 Jan 22; 105(3):322-7.
    View in: PubMed
    Score: 0.043
  13. Taking a Stand Against Air Pollution - The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. Glob Heart. 2021 01 28; 16(1):8.
    View in: PubMed
    Score: 0.040
  14. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. Am J Med. 2018 08; 131(8):972.e1-972.e7.
    View in: PubMed
    Score: 0.033
  15. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017 Nov; 44(4):457-465.
    View in: PubMed
    Score: 0.032
  16. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
    View in: PubMed
    Score: 0.031
  17. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 08 11; 375(6):534-44.
    View in: PubMed
    Score: 0.029
  18. Noninvasive, medical management for non-ST-elevation acute coronary syndromes. Am Heart J. 2008 Mar; 155(3):397-407.
    View in: PubMed
    Score: 0.016
  19. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006 Dec; 152(6):1042-50.
    View in: PubMed
    Score: 0.015
  20. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J. 2006 Oct; 152(4):641-7.
    View in: PubMed
    Score: 0.015
  21. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6.
    View in: PubMed
    Score: 0.015
  22. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2006 Sep 01; 98(5):624-7.
    View in: PubMed
    Score: 0.015
  23. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2006 Jun; 151(6):1205-13.
    View in: PubMed
    Score: 0.015
  24. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J. 2006 Jan; 151(1):16-24.
    View in: PubMed
    Score: 0.014
  25. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2005 Sep 15; 96(6):750-5.
    View in: PubMed
    Score: 0.014
  26. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.
    View in: PubMed
    Score: 0.014
  27. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005 May; 12(5):431-8.
    View in: PubMed
    Score: 0.014
  28. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005 Mar; 149(3):474-81.
    View in: PubMed
    Score: 0.013
  29. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Can J Cardiol. 2004 Jun; 20(8):773-8.
    View in: PubMed
    Score: 0.013
  30. Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. Am J Med. 2003 Dec 01; 115(8):613-9.
    View in: PubMed
    Score: 0.012
  31. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol. 2003 Aug 01; 92(3):330-3.
    View in: PubMed
    Score: 0.012
  32. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003 Jul 15; 92(2):136-40.
    View in: PubMed
    Score: 0.012
  33. Poverty, process of care, and outcome in acute coronary syndromes. J Am Coll Cardiol. 2003 Jun 04; 41(11):1948-54.
    View in: PubMed
    Score: 0.012
  34. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003 Feb 05; 41(3):371-80.
    View in: PubMed
    Score: 0.012
  35. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.
    View in: PubMed
    Score: 0.011
  36. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002 Aug; 14(1):33-42.
    View in: PubMed
    Score: 0.011
  37. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology. 2002; 98(4):195-201.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.